Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries

OBJECTIVES: Seven years after the introduction of direct-acting antivirals (DAAs) for the treatment of hepatitis C, high prices remain a barrier for treatment programs worldwide. This study seeks to describe current prices for originator DAAs in 50 countries and evaluate the relationship between pri...

Descripción completa

Detalles Bibliográficos
Autores principales: Barber, Melissa J., Gotham, Dzintars, Khwairakpam, Giten, Hill, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646676/
https://www.ncbi.nlm.nih.gov/pubmed/33251019
http://dx.doi.org/10.1016/j.jve.2020.06.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646676/
https://www.ncbi.nlm.nih.gov/pubmed/33251019
http://dx.doi.org/10.1016/j.jve.2020.06.001

Ejemplares similares